Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Andréasson, Kristofer ^a   Saxne, Tore ^a   Scheja, Agneta ^a   Bartosik, Izabela ^a   Mandl, Thomas ^b   Hesselstrand, Roger ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALGRANULIN; CYCLOPHOSPHAMIDE; FECAL CALPROTECTIN; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CINERADIOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FECES LEVEL; FECES PROTEIN LEVEL; FEMALE; HOSPITAL PERSONNEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL DEFICIENCY; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS; CHEMISTRY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; MIDDLE AGED; PATHOLOGY;

AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 84896847058     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4475     Document Type: Article

References (44)

1. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41:56-66. 10.1016/j.dld.2008.05.008, 18602356.
2. Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 2001, 37:85-96.
3. Andreasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 2011, 270:50-57. 10.1111/j.1365-2796.2010.02340.x, 21205026.
4. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008, 53:1163-1174. 10.1007/s10620-007-0018-8, 17934861.
5. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
6. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998, 57:682-686. 1752504, 9924211.
7. Schmeiser T, Saar P, Jin D, Noethe M, Müller A, Soydan N, Hardt PD, Jaeger C, Distler O, Roeb E, Bretzel RG, Müller-Ladner U. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int 2012, 32:2471-2478. 10.1007/s00296-011-1988-6, 21769490.
8. Marie I, Levesque H, Ducrotte P, Denis P, Benichou J, Hellot MF, Cailleux N, Le Loet X, Joly P, Lauret P, Courtois H. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998, 41:1874-1883. 10.1002/1529-0131(199810)41:10<1874::AID-ART21>3.0.CO;2-T, 9778230.
9. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 2012, 32:165-168. 10.1007/s00296-010-1595-y, 20711592.
10. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012, 14:22-29. 10.1007/s11926-011-0217-3, 22105546.
11. Pakozdi A, Wilson H, Black CM, Denton CP. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clin Exp Rheumatol 2009, 27:5-8.
12. Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford) 2010, 49:1770-1775. 10.1093/rheumatology/keq147, 20530510.
13. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34:50-54. 10.1080/00365529950172835, 10048733.
14. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009, 86:557-566. 10.1189/jlb.1008647, 19451397.
15. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992, 27:793-798. 10.3109/00365529209011186, 1411288.
16. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012, 12:5. 10.1186/1471-230X-12-5, 3267677, 22233279.
17. Montalto M, Santoro L, Dalvai S, Curigliano V, D'Onofrio F, Scarpellini E, Cammarota G, Panunzi S, Gallo A, Gasbarrini A, Gasbarrini G. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis 2008, 26:183-186. 10.1159/000116777, 18431069.
18. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, Hu PJ, Chen MH. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012, 18:1894-1899. 10.1002/ibd.22861, 22238138.
19. Andréasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 1980, 2013. doi:10.1136/annrheumdis-2013-203618.
20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer S, Talal N, Weisman M, the European Study Group on Classification Criteria for Sjögren's Syndrome Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558. 1754137, 12006334, the European Study Group on Classification Criteria for Sjögren's Syndrome.
21. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003, 21:S15-S18.
22. Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Morel J, Pedriger A, Puechal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Zarnitsky C, Labetoulle M, Ravaud P, Mariette X. European League against Rheumatism Sjögren's Syndrome Disease Activity Index and European League against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res (Hoboken) 2013, 65:1358-1364. 10.1002/acr.21991, 23436737.
23. Madsen OR. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?. Clin Rheumatol 2011, 30:1577-1582. 10.1007/s10067-011-1847-6, 21956233.
24. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007, 102:803-813. 10.1111/j.1572-0241.2007.01126.x, 17324124.
25. Lasson A. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing]. Lakartidningen 2010, 107:2645-2649.
26. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010, 16:1091-1092. 10.1002/ibd.21136, 19834972.
27. Moreno Chulilla JA, Romero Colas MS, Gutierrez Martin M. Classification of anemia for gastroenterologists. World J Gastroenterol 2009, 15:4627-4637. 10.3748/wjg.15.4627, 2754510, 19787825.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
29. Brennan P, Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ 1992, 304:1491-1494. 10.1136/bmj.304.6840.1491, 1882212, 1611375.
30. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007, 8:38. 10.1186/1745-6215-8-38, 2169260, 18039364.
31. Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013, 37:613-621. 10.1111/apt.12221, 23347334.
32. Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007, 50:1697-1706. 10.1007/s10350-007-0303-9, 17762964.
33. Hammer HB, Odegard S, Fagerhol MK, Landewe R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1093-1097. 1954700, 17234650.
34. van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, Cats H, Vogl T, Roth J, van den Berg WB. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 2012, 64:1466-1476. 10.1002/art.34315, 22143922.
35. Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis-frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012, 47:435-444. 10.3109/00365521.2011.648953, 22229862.
36. Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003, 125:1598-1605. 10.1053/j.gastro.2003.08.035, 14724811.
37. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128:1172-1178. 10.1053/j.gastro.2005.03.020, 15887101.
38. Mandl T, Granberg V, Apelqvist J, Wollmer P, Manthorpe R, Jacobsson LT. Autonomic nervous symptoms in primary Sjogren's syndrome. Rheumatology (Oxford) 2008, 47:914-919. 10.1093/rheumatology/ken107, 18411214.
39. Hammar O, Ohlsson B, Wollmer P, Mandl T. Impaired gastric emptying in primary Sjogren's syndrome. J Rheumatol 2010, 37:2313-2318. 10.3899/jrheum.100280, 20810502.
40. Manetti M, Neumann E, Müller A, Schmeiser T, Saar P, Milia AF, Endlicher E, Roeb E, Messerini L, Matucci-Cerinic M, Ibba-Manneschi L, Müller-Ladner U. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008, 58:2866-2873. 10.1002/art.23806, 18759276.
41. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996, 8:569-575. 10.1097/00002281-199611000-00012, 9018461.
42. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013, 50:53-61. 10.1258/acb.2012.011272, 23129721.
43. Burri E, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta 2013, 416:41-47.
44. Ibba-Manneschi L, Del Rosso A, Pacini S, Tani A, Bechi P, Matucci Cerinic M. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann Rheum Dis 2002, 61:754-756. 1754189, 12117690.